WO2011011061A3 - Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy - Google Patents

Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy Download PDF

Info

Publication number
WO2011011061A3
WO2011011061A3 PCT/US2010/002045 US2010002045W WO2011011061A3 WO 2011011061 A3 WO2011011061 A3 WO 2011011061A3 US 2010002045 W US2010002045 W US 2010002045W WO 2011011061 A3 WO2011011061 A3 WO 2011011061A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
lymphangiogenic
lymphangiogenesis
angiogenic
cancer therapy
Prior art date
Application number
PCT/US2010/002045
Other languages
French (fr)
Other versions
WO2011011061A2 (en
Inventor
Calvin Kuo
Frank Kuhnert
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of WO2011011061A2 publication Critical patent/WO2011011061A2/en
Publication of WO2011011061A3 publication Critical patent/WO2011011061A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition, containing at least one antagonist or antimir against miR-126, and a suitable carrier. The composition is advantageously used in the treatment of tumors.
PCT/US2010/002045 2009-07-21 2010-07-21 Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy WO2011011061A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21383809P 2009-07-21 2009-07-21
US61/213,838 2009-07-21

Publications (2)

Publication Number Publication Date
WO2011011061A2 WO2011011061A2 (en) 2011-01-27
WO2011011061A3 true WO2011011061A3 (en) 2011-03-17

Family

ID=43499578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/002045 WO2011011061A2 (en) 2009-07-21 2010-07-21 Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy

Country Status (1)

Country Link
WO (1) WO2011011061A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003466A1 (en) * 2010-07-02 2012-01-05 Ensysce Biosciences, Inc. Single-walled carbon nanotube/sirna complexes and methods related thereto
EP2673363B1 (en) 2011-02-11 2017-08-23 The Rockefeller University Treatment of angiogenesis disorders
CN102716730B (en) * 2012-07-11 2014-04-02 济南大学 Preparation method for novel nano magnetic cyclodextrin/graphene biological adsorption material
US10801026B2 (en) * 2015-10-15 2020-10-13 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
CN106566838B (en) * 2016-11-14 2019-11-01 上海伯豪生物技术有限公司 A kind of miR-126 full-length gene knockout kit and its application based on CRISPR-Cas9 technology
EP3917573A4 (en) * 2019-01-28 2022-12-07 The Administrators of The Tulane Educational Fund Crispr-based methods and novel compositions for treating vascular disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261218A1 (en) * 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
US20080241198A1 (en) * 2005-04-12 2008-10-02 Yijia Liu Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261218A1 (en) * 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
US20080241198A1 (en) * 2005-04-12 2008-10-02 Yijia Liu Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU ET AL.: "MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo.", LUNG CANCER., vol. 66, no. 2, 2009, pages 169 - 75, XP026718909, DOI: doi:10.1016/j.lungcan.2009.01.010 *

Also Published As

Publication number Publication date
WO2011011061A2 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
SG10201903119QA (en) Polypeptide vaccine
AP3346A (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
EP2170062A4 (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2257647A4 (en) MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER
IL225597A0 (en) Pharmaceutical composition, methods for treating and uses thereof
AP2012006135A0 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof.
WO2013056148A3 (en) Scd1 antagonists for treating cancer
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
WO2011011061A3 (en) Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy
WO2012005550A3 (en) Pharmaceutical composition for treating gallbladder carcinoma, and method for inhibiting growth and metastasis of gallbladder carcinoma and treating gallbladder carcinoma, using same
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
EP2224919A4 (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
PH12015501088A1 (en) Dimeric compounds
WO2009158374A3 (en) Inhibitors of akt activity
WO2008119771A3 (en) Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors
PL2448920T3 (en) Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine
EP2362904A4 (en) Method for treating or preventing bladder cancer using the depdc1 polypeptide
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
EP3524274A3 (en) Managing the treatment of a cellular proliferative disorder using hom-1 expression
WO2013106460A3 (en) Compositions and methods for treating malignant astrocytomas
EP2724725A4 (en) Pharmaceutical composition for treating scars on the skin, and method for treating scars on the skin using same
EP3865488A4 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10802550

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10802550

Country of ref document: EP

Kind code of ref document: A2